PMID- 34941058
OWN - NLM
STAT- MEDLINE
DCOM- 20220217
LR  - 20230103
IS  - 1536-5964 (Electronic)
IS  - 0025-7974 (Print)
IS  - 0025-7974 (Linking)
VI  - 100
IP  - 51
DP  - 2021 Dec 23
TI  - Effect and safety of anlotinib combined with S-1 for recurrent or metastatic 
      esophageal cancer patients who refused or were intolerant to intravenous 
      chemotherapy.
PG  - e28126
LID - 10.1097/MD.0000000000028126 [doi]
LID - e28126
AB  - This study aimed to evaluate the effect and safety of anlotinib combined with S-1 
      in the treatment of recurrent or metastatic esophageal cancer patients who 
      refused or were intolerant to intravenous chemotherapy.This study retrospectively 
      reviewed 22 recurrent or metastatic esophageal cancer patients who refused or 
      were intolerant to intravenous chemotherapy between June 1, 2018 and February 28, 
      2019. All patients did not previously receive anlotinib or S-1.Of 22 patients, 20 
      patients had squamous cell cancer. Seventeen patients received at least 2 cycles 
      of anlotinib plus S-1. The objective response rate (ORR) was 35.3%, and the 
      disease control rate (DCR) was 82.4%. The median progression-free survival (PFS) 
      was 3.5 months, and median overall survival (OS) was 5.2 months. In the 
      first-line treatment subgroup, the ORR was 50%, the DCR was 80%, the median PFS 
      was 4.5 months, and the median OS was 5.8 months. In the second-line and above 
      treatment subgroup, the ORR was 14.3%, the DCR was 85.7%, the median PFS was 
      3.0 months, and the median OS was 3.7 months. The main adverse events (AEs) of 
      anlotinib combined with S-1 were fatigue (58.8%), hypertension (47.1%), 
      hemoptysis (29.4%), anemia (29.4%), nausea (23.5%), liver function damage 
      (23.5%), albuminuria (17.6%), abdominal pain (17.6%), leukopenia (17.6%), 
      neutropenia (11.8%), fever (11.8%), and hand-foot syndrome (11.8%). Grade 3 AEs 
      included nausea (5.9%) and hypertension (5.9%), and no grade 4 or more AEs were 
      reported.Anlotinib combined with S-1 achieved promising disease control and 
      satisfactory survival with tolerable safety in recurrent metastatic esophageal 
      cancer who refused or were intolerant to intravenous chemotherapy.
CI  - Copyright (c) 2021 the Author(s). Published by Wolters Kluwer Health, Inc.
FAU - Cai, Jing
AU  - Cai J
AD  - The Second Affiliated Hospital of Nanchang University, Nanchang, Jiangxi 
      Province, China.
FAU - Zhou, Shan
AU  - Zhou S
AD  - Medical College of Nanchang University, Nanchang, Jiangxi Province, China.
FAU - Luo, Yuxi
AU  - Luo Y
AD  - Medical College of Nanchang University, Nanchang, Jiangxi Province, China.
FAU - Liu, Anwen
AU  - Liu A
AUID- ORCID: 0000-0001-5279-1068
AD  - The Second Affiliated Hospital of Nanchang University, Nanchang, Jiangxi 
      Province, China.
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Medicine (Baltimore)
JT  - Medicine
JID - 2985248R
RN  - 0 (Antimetabolites, Antineoplastic)
RN  - 0 (Drug Combinations)
RN  - 0 (Indoles)
RN  - 0 (Quinolines)
RN  - 0 (anlotinib)
RN  - 150863-82-4 (S 1 (combination))
RN  - 1548R74NSZ (Tegafur)
RN  - 5VT6420TIG (Oxonic Acid)
SB  - IM
MH  - Antimetabolites, Antineoplastic/*therapeutic use
MH  - Drug Combinations
MH  - Esophageal Neoplasms/*drug therapy/pathology
MH  - Humans
MH  - Indoles/administration & dosage/*therapeutic use
MH  - Neoplasm Recurrence, Local
MH  - Neoplasms, Squamous Cell/*drug therapy/*pathology
MH  - Oxonic Acid/*therapeutic use
MH  - Quinolines/administration & dosage/*therapeutic use
MH  - Retrospective Studies
MH  - Tegafur/*therapeutic use
MH  - Treatment Outcome
PMC - PMC8702052
COIS- The authors report no conflicts of interest.
EDAT- 2021/12/24 06:00
MHDA- 2022/02/19 06:00
PMCR- 2021/12/23
CRDT- 2021/12/23 14:07
PHST- 2021/05/04 00:00 [received]
PHST- 2021/11/15 00:00 [accepted]
PHST- 2021/12/23 14:07 [entrez]
PHST- 2021/12/24 06:00 [pubmed]
PHST- 2022/02/19 06:00 [medline]
PHST- 2021/12/23 00:00 [pmc-release]
AID - 00005792-202112230-00034 [pii]
AID - MD-D-21-03405 [pii]
AID - 10.1097/MD.0000000000028126 [doi]
PST - ppublish
SO  - Medicine (Baltimore). 2021 Dec 23;100(51):e28126. doi: 
      10.1097/MD.0000000000028126.